L'intérêt à découvert pour Sarepta Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Sarepta Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Rapport sur les intérêts à découvert

SAREPTA THERAPEUTICS INC

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SRPT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Sarepta Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 18% bearish. Among these notable options, 4 are puts, totaling $282,850, and 7 are calls, amounting to $233,830.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Sarepta Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Sarepta Therapeutics stands at 172.62, with a total volume reaching 607.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Sarepta Therapeutics, situated within the strike price corridor from $70.0 to $140.0, throughout the last 30 days.
<h3>Sarepta Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742584593_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.9</td>
<td>$30.3</td>
<td>$30.3</td>
<td>$100.00</td>
<td>$99.9K</td>
<td align="right">637</td>
<td align="right">63</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.4</td>
<td>$29.8</td>
<td>$30.4</td>
<td>$100.00</td>
<td>$72.9K</td>
<td align="right">637</td>
<td align="right">24</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$68.2</td>
<td>$64.2</td>
<td>$66.16</td>
<td>$140.00</td>
<td>$66.1K</td>
<td align="right">10</td>
<td align="right">10</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$24.6</td>
<td>$24.1</td>
<td>$24.3</td>
<td>$95.00</td>
<td>$43.7K</td>
<td align="right">142</td>
<td align="right">19</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$8.9</td>
<td>$8.4</td>
<td>$8.65</td>
<td>$80.00</td>
<td>$43.2K</td>
<td align="right">548</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 1,192,820, the price of SRPT is down -0.2% at $73.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>What The Experts Say On Sarepta Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $141.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Perform, setting a price target of $105. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $163. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $163. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $202. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Sell, setting a price target of $75. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

SRPT

This Is What Whales Are Betting On Sarepta Therapeutics

WIIM

Sarepta Therapeutics shares are trading lower after Scotiabank cut its price target on the stock from $105 to $80.

Scotiabank analyst Louise Chen maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform and lowers the price target from $105 to $80.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $80

Sarepta Therapeutics shares are trading higher. The stock fell on Tuesday after the company reported a patient death following treatment with Elevidys.

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and maintains $163 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Sarepta Therapeutics, Maintains $163 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

Deutsche Bank analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Hold and lowers the price target from $124 to $99.

Deutsche Bank Maintains Hold on Sarepta Therapeutics, Lowers Price Target to $99

U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve&#8217;s <a href="https://in.benzinga.com/government/regulations/25/03/44364688/feds-march-meeting-expected-to-signal-no-hurry-on-rate-cuts-as-powell-likely-to-tread-carefully">interest rate decision</a>. The Dow Jones Industrial Average slipped 0.6% to 41,581.31, while the S&amp;P 500 lost nearly 1.1% to 5,614.66. The Nasdaq tumbled 1.7% to 17,504.12.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
Nvidia&#8217;s stock closed down 3.43% at $115.43, after reaching an intraday high of $119.02 and a low of $114.54. The stock&#8217;s 52-week range is $75.61 to $153.13. Nvidia CEO Jensen Huang announced a <a href="https://www.benzinga.com/tech/25/03/44383445/nvidia-ceo-jensen-huang-announces-gm-partnership-the-time-for-autonomous-vehicles-has-arrived">partnership with GM</a> to integrate Nvidia&#8217;s Blackwell-based AI technology into self-driving and manufacturing. At GTC 2025, Huang also highlighted the rise of &#8220;physical AI&#8221; and Nvidia&#8217;s growing role in various industries.
Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
Meta&#8217;s shares fell 3.73%, closing at $582.36, with an intraday high of $600.25 and a low of $574.66. The stock&#8217;s 52-week high and low are $740.89 and $414.5, respectively. Analysts at Wolfe Research predict that Meta could generate $30-40 billion in revenue from its&nbsp;<a href="https://in.benzinga.com/markets/25/03/44374847/meta-could-rake-in-30-40-billion-in-revenue-from-whatsapp-business-messaging-predicts-analyst">business messaging services</a>, which is currently undervalued by the market.
Sarepta Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)
Sarepta&#8217;s stock plunged 27.44% to close at $73.54, with a high of $81.87 and a low of $73.06, marking a new 52-week low. The decline followed the company&#8217;s report of a patient death after treatment with its&nbsp;<a href="https://in.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges">Elevidys gene therapy</a>, the only approved therapy for Duchenne muscular dystrophy.
D-Wave Quantum Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)
D-Wave Quantum shares decreased by 3.40%, closing at $10.80, with a high of $11.50 and a low of $9.48. The stock&#8217;s 52-week range is $0.75 to $11.50. The decline occurred as <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44385434/d-wave-quantum-shares-traded-lower-tuesday-what-happened">quantum stocks</a> faced volatility ahead of Nvidia&#8217;s Quantum Day, part of the GPU Technology Conference.
Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s shares dropped 5.34%, ending the day at $225.31, with an intraday high of $230.10 and a low of $222.28. The 52-week range is $138.80 to $488.54. However, the Elon Musk-led company&#8217;s shares rose in the after-hours trading by almost 1.1%. The decline in regular trading followed the announcement of a <a href="https://in.benzinga.com/news/large-cap/25/03/44389027/tesla-takes-another-hit-with-nvidia-gm-self-driving-partnership">partnership</a> between Nvidia and General Motors on self-driving vehicles, impacting Tesla&#8217;s market position.
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44389960/cathie-woods-big-tuesday-bet-ark-pours-7-8-million-into-tempus-ai-despite-stock-stumble">Cathie Wood&#8217;s Big Tuesday Bet: Ark Pours $7.8 Million Into Tempus AI Despite Stock Stumble</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

NVDA

QBTS

TSLA

Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $134.33, a high estimate of $202.00, and a low estimate of $75.00. Highlighting a 2.21% decrease, the current average has fallen from the previous average price target of $137.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1742328026_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Sarepta Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sarepta Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 65.94%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sarepta Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.57%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below the industry average at 0.88, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Sarepta Therapeutics

Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York. Investors weighed the economic impact of potential tariffs from the Trump administration while questioning whether the long-standing dominance of <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44379453/equity-exposure-plummets-cash-holdings-jump-as-investors-rethink-us-exceptionalism-bank-of-america-survey">U.S. equities has peaked. </a>
The S&amp;P 500 fell 1.1%, while the tech-heavy Nasdaq 100 dropped 1.5%. Blue-chip stocks provided no relief with the Dow Jones down 0.8%.
Data from Bank of America's Global Fund Manager Survey, released Tuesday, signaled a significant shift in asset allocation. Investor exposure to U.S. equities plunged 40 percentage points month-over-month to a net 23% underweight, the lowest level since June 2023. 
The Federal Reserve is set to hold its second policy meeting of the year on Wednesday. While markets widely expect interest rates to remain at 4%-4.25%, investors brace for updated economic projections that may reflect higher inflation estimates due to the tariff impact.
All Magnificent Seven tech giants traded in the red on Tuesday, with the Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>) hitting a seven-month low.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) tumbled 14% month-to-date, on track for its worst monthly performance since October 2022. Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has plummeted 21% since February, marking its worst two-month decline since November 2008.
Amid rising economic uncertainty, gold surged over 1% to $3,040 per ounce, as haven demand intensified. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) is on track for its sixth consecutive session of gains, the longest streak since April 2024.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) remained under pressure, sliding 2.6% to $81,855.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,492.66</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,050.11</td>
<td>-0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,612.52</td>
<td>-1.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,507.30</td>
<td>-1.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1 p.m. ET </figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 1.1% to $560.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) dropped 0.9% to $415.47.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;sunk 1.6% to $475.28.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 1.1% to $203.16. </li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, yet still down 0.2%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) was the worst sector performer, down 1.8%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
<ul>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) tumbled 7.7% in reaction to quarterly earnings. </li>
<li>Other stocks reacting to corporate earnings included KE Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>), down 10.3%, Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>), up 11.9% and Elbit System Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>), up 11%. </li>
<li>Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) rallied 11.6% after Morgan Stanley upgraded the stock from Underweight to Equal-weight.</li>
<li>Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) plunged 21% after reporting the death of a Duchenne muscular dystrophy patient who had been treated with Elevidys.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44375798/apple-iphone-shipments-in-china-drop-21-january-goldman-sachs-remains-bullish">Apple iPhone Shipments In China Drop 21% In January, Goldman Sachs Remains Bullish</a></li>
</ul>
Photo: Shutterstock

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

Tech

ETFs

$BTC

BEKE

SPDR Dow Jones Industrial Average ETF Trust

ESLT

GOOGL

LCID

MAGS

XPEV

Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday?

U.S. stocks traded lower midway through trading, with the S&amp;P 500 falling around 1% on Tuesday.
The Dow traded down 0.81% to 41,504.25 while the NASDAQ dipped 1.44% to 17,551.39. The S&amp;P 500 also fell, dropping, 1.04% to 5,616.32.
Check This Out: <a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a>
Leading and Lagging Sectors Materials shares fell by just 0.3% on Tuesday.
In trading on Tuesday, communication services shares dipped by 2.6%.
Top Headline
IHS Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) posted better-than-expected fourth-quarter results.
IHS Holding reported quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 9 cents per share. The company reported quarterly sales of $437.822 million which beat the analyst consensus estimate of $424.001 million.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares shot up 57% to $6.88 after the company announced it submitted an application for four new federal funding opportunities.</li>
<li>Shares of Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>)got a boost, surging 16% to $26.96 following fourth-quarter results.</li>
<li>FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) shares were also up, gaining 18% to $10.72 after the company reported better-than-expected fourth-quarter financial results. Also, the company announced a new $150 million share repurchase program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Gyre Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares dropped 27% to $9.02 following fourth-quarter results.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) were down 22% to $78.60 after the company reported a patient death following treatment with Elevidys.</li>
<li>HUYA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) was down, falling 17% to $3.7499 following a fourth-quarter revenue miss.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $66.84 while gold traded up 1.2% at $3,042.70.
Silver traded up 1.5% to $34.805 on Tuesday, while copper rose 1% to $5.0080.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.61%, Germany's DAX 40 jumped 0.98% and France's CAC 40 gained 0.50%. Spain's IBEX 35 Index rose 1.58%, while London's FTSE 100 rose 0.29%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 1.20%, China's Shanghai Composite Index gaining 0.11%, Hong Kong's Hang Seng Index surging 2.46% and India's BSE Sensex gaining 1.53%.
Economics
<ul>
<li>U.S. housing starts surged 11.2% month-over-month to an annualized rate of 1.501 million in February following a revised 1.35 million in January.</li>
<li>Building permits declined by 1.2% to an annualized rate of 1.456 million in February.</li>
<li>U.S. import prices increased by 0.4% in February, versus market estimates of a 0.1% decline.</li>
<li>U.S. export prices rose by 0.1% month-over-month in February.</li>
<li>U.S. industrial production increased by 0.7% in February, surpassing market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44325485/wall-streets-most-accurate-analysts-spotlight-on-3-real-estate-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Trading Ideas

ADTX

FINV

GYRE

HROW

HUYA

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge

<h3>Gainers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares increased by 49.0% to $0.13 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 24.37% to $23.01. The company's market cap stands at $299.4 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares increased by 20.0% to $1.13. The market value of their outstanding shares is at $35.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 19.85% to $2.9. The market value of their outstanding shares is at $122.6 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock increased by 19.12% to $1.58. The market value of their outstanding shares is at $30.5 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 18.67% to $19.32. The market value of their outstanding shares is at $108.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 47.2% to $0.45 during Tuesday's regular session. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 40.6% to $0.28. The company's market cap stands at $4.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 27.76% to $0.92. The company's market cap stands at $71.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock fell 26.51% to $9.03. The company's market cap stands at $774.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 23.2% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares declined by 20.82% to $80.25. The company's market cap stands at $7.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATXI

HURA

HYPR

JAGX

OSRH

SYRS

TNXP

VRPX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and maintains $202 price target.

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $202 Price Target

On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
The company reported a patient death following treatment with Elevidys, having suffered acute liver failure.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42883730/solid-biosciences-outpaces-competitors-in-duchenne-gene-therapy-development" rel="noreferrer noopener">Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development</a>
The company <a target="_blank" href="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5" rel="noreferrer noopener">says</a> although it is not a new safety signal and the benefit-risk of Elevidys remains positive, acute liver failure leading to death represents a severity of acute liver injury not previously reported for Elevidys, which to date has been used to treat more than 800 patients in clinical trials or as a prescribed therapy.
In addition, testing revealed that this patient had a recent cytomegalovirus (CMV) infection, which the treating physician identified as a possible contributing factor. CMV can infect and damage the liver, a condition known as CMV hepatitis.
Elevidys is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of Elevidys micro-dystrophin in skeletal muscle.
In January, Sarepta Therapeutics&nbsp;released topline results from Part 2 of the EMBARK <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43232532/sarepta-therapeutics-duchenne-gene-therapy-shows-sustained-benefits-and-disease-stabilization-at-two-years" rel="noreferrer noopener">Phase 3 study of Elevidys</a>.
Despite being one year older (average age 7.18 years) than those treated in Part 1 (average age 5.98 years), crossover-treated patients showed clinically meaningful and statistically significant functional benefit for NSAA, Time to Rise (TTR) and 10-meter walk/run (10MWR) function tests compared with a pre-specified, propensity-weighted external control group.
In June 2024, the FDA approved the labeled indication for&nbsp;Elevidys to include individuals with Duchenne muscular dystrophy who have a confirmed mutation in the&nbsp;DMD gene and are at&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39437296/sareptas-expanded-fda-approval-for-elevidys-potentially-shaping-future-fda-reviews-" rel="noreferrer noopener">least&nbsp;four years old</a>.
Price Action: SRPT stock is down 22.90% at $78.10 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44375605/tencent-musics-q4-revenue-beats-street-view-but-monthly-active-users-fall-over-3" target="_blank" rel="noreferrer noopener">Tencent Music&#8217;s Q4 Revenue Beats Street View, But Monthly Active Users Fall Over 3%</a></li>
</ul>

Biotech

Health Care

General

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Sarepta Therapeutics shares are trading lower after the company reported a patient death following treatment with Elevidys.

<a href="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5" title="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5">https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5</a>

Sarepta Therapeutics Reports A Patient Death With Duchenne Muscular Dystrophy Following Treatment With Elevidys, Having Suffered Acute Liver Failure

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 58.9% to $29.39 during Tuesday's pre-market session. The company's market cap stands at $382.4 million. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock increased by 52.68% to $0.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock increased by 20.06% to $28.0. The company's market cap stands at $997.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares increased by 18.37% to $0.56. The company's market cap stands at $29.0 million. The company's, Q2 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 17.46% to $0.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 16.07% to $0.68. The company's market cap stands at $48.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 35.9% to $0.55 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares decreased by 26.26% to $0.94. The company's market cap stands at $73.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 22.79% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 21.56% to $79.5. The market value of their outstanding shares is at $7.5 billion. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock decreased by 18.55% to $2.02. The company's market cap stands at $17.3 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock fell 17.69% to $2.7. The company's market cap stands at $365.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CTOR

INNV

SCNX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, Arrowhead Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company&#8217;s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">complement-mediated diseases</a>.
ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases.&nbsp;
The dysregulated activity of the complement system can contribute to tissue injury and the progression of the disease. By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating the activation of the complement cascade.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44223155/veren-soars-on-whitecap-merger-deal-details" rel="noreferrer noopener">Veren Soars On Whitecap Merger Deal: Details</a>
The company plans to present additional results at a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44216024/arrowhead-pharmaceuticals-announces-topline-results-from-part-2-of-phase-12-study-of-aro-c3-in-pat" rel="noreferrer noopener">medical meeting in 2025</a>.
Select Phase 1/2 Study Results
<ul>
<li>Pharmacodynamic effects: Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24.</li>
<li>Maximum mean reduction in serum AH50 (alternative pathway hemolytic assay) of 85% and mean sustained reduction greater than 76%.</li>
<li>Maximum mean reduction in Wieslab AP (alternative pathway) of 100% and mean sustained reduction greater than 89%.</li>
<li>Duration of effect supportive of once every three months or less frequent subcutaneous dosing in later-stage studies</li>
<li>Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was 41%, and the maximum individual reduction was 89%.</li>
</ul>
In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals&#8217; New Drug Application for investigational plozasiran for familial chylomicronemia syndrome, a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43067733/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-u-s-fda-of-plozasiran-fo" rel="noreferrer noopener">advisory committee meeting</a>.
In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with Sarepta Therapeutics Inc. Arrowhead receives a $500 million upfront payment and $325 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43591315/arrowhead-pharmaceuticals-announces-closing-of-global-license-and-collaboration-agreement-with-sar" rel="noreferrer noopener">through Sarepta stock</a>.
Price Action: ARWR stock is down 8.72% at $15.49 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44220746/pfizers-covid-19-shot-partner-biontech-reports-q4-profit-but-2025-guidance-falls-short-on-expectations" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations</a></li>
</ul>
Photo via Shutterstock.

ARWR

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Scotiabank analyst Louise Chen initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform rating and announces Price Target of $105.

Initiation

Scotiabank Initiates Coverage On Sarepta Therapeutics with Sector Perform Rating, Announces Price Target of $105

Press Releases

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Legal

Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Comments

Sarepta Therapeutics

Intérêt court

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL